Abstract
18F-2-deoxy-d-glucose (FDG) has been the primary tracer for positron emission tomography (PET) in urologic malignancy. The primary clinical application of PET–CT in urology relates to the management of the urologic malignancies, including renal cancer, bladder cancer, prostate cancer, and testicular cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
For Further Reading
Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [(18)F] FDG PET in characterizing renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30:1236–45.
De Hullu JA, Pruim J, Que TH, et al. Noninvasive detection of inguinofemoral lymph node metastases in squamous cell cancer of the vulva by L-[1e11C] tyrosine positron emission tomography. Int J Gynecol Cancer. 1999;9(2):141e6.
De Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using C-11-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging. 2002;29:1283–8.
Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22:2167–71.
Hain SF, O’Doherty MJ, Timothy AR, et al. Fluoro deoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer. 2000;83:863–9.
Ho KC, Lai CH, Wu TI, et al. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging. 2008;35(3):484–92.
Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36(3):362–72.
Lamoreaux WT, Grigsby PW, Dehdashti F, et al. FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys. 2005;62(3):733–7.
Lassen U, Daugaard G, Eigtved A, et al. Whole body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 2003;30:396–402.
Price DT, Coleman RE, Liano RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18F] fluorocholine and (18F) fluoro deoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273–80.
Risum S, Hogdall C, Loft A, et al. The diagnostic value of PET-CT for primary ovarian cancer- a prospective study. Gynecol Oncol. 2007;105(1):145–9.
Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, Czernin J. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol. 2002;57:56–62.
Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDGPET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys. 2003;56(2):489–93.
Toth G, Lengyel Z, Balkay L, Salah MA, Tron L, Toth C. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol. 2005;173:66–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer India
About this chapter
Cite this chapter
Pradhan, P.K., Mubalsha, R. (2015). Application of PET–CT in Genitourinary Malignancies. In: Das, B. (eds) Positron Emission Tomography. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2098-5_14
Download citation
DOI: https://doi.org/10.1007/978-81-322-2098-5_14
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-2097-8
Online ISBN: 978-81-322-2098-5
eBook Packages: MedicineMedicine (R0)